Gip

Fatty Liver Disease

Dr Adnan Aghaprotein_peptidePhase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

26 Active assets in the Fatty Liver Disease cohort.

Asset / Sponsor	Phase	Rating
Metformin Leiden University Medical Center	Phase 4	BBB
Alpha Tocopherol Yuen Kah Hay	Phase 4	BB
Empagliflozin Seoul National University Bundang Hospital	Phase 4	BB
Rilpivirine Fundacion SEIMC-GESIDA	Phase 4	BB
Pioglitazone Seoul National University Bundang Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Gip is also rated in:

type 2 diabetes mellitusActive

CCC

Indicative · Phase 1

48 / 100

metabolic dysfunction-associated steatohepatitisActive

CC

Indicative · Phase 1/2

47 / 100

metabolic dysfunction-associated steatotic liver diseaseActive

CC

Indicative · Phase 1/2

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.